Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioVie ( (BIVI) ) has issued an update.
On June 23, 2025, BioVie Inc.’s stockholders approved a reverse stock split of its Class A common stock, allowing the board to consolidate shares at a ratio between 1-for-5 and 1-for-10. On June 26, 2025, the board decided on a 1-for-10 reverse stock split, effective July 7, 2025, which will adjust the trading of shares on The Nasdaq Capital Market and affect stock options and warrants proportionately.
The most recent analyst rating on (BIVI) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.
Spark’s Take on BIVI Stock
According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.
BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.
To see Spark’s full report on BIVI stock, click here.
More about BioVie
Average Trading Volume: 422,607
Technical Sentiment Signal: Strong Sell
Current Market Cap: $19.13M
For an in-depth examination of BIVI stock, go to TipRanks’ Overview page.